Discussing Obesity With Patients With Cancer
57% of respondents indicated that they discuss obesity with their patients after they are diagnosed with cancer, however nearly 40% of those polled indicated that they do not discuss the topic.
While the majority, 66%, of respondents said that they believe oncology care teams should advocate for policy changes in regards to weight management services and society factors related to obesity, 34% believe that this is not the job of the oncology care team.
A large portion, 84%, of readers who responded to the poll indicated that oncology care teams currently do not do enough to educate patients on the cancer risk associated with obesity--highlighting the need for ASCO's initiative.
The American Society of Clinical Oncology recently released a position statement on obesity and cancer.
While research related to obesity's effect on cancer is ongoing, it is clear that obesity is becoming a leading preventable cause of cancer (overtaking more well-known causes such as tobacco) and it's an important issue for oncologists to be informed about.
We asked Cancer Therapy Advisor readers to weigh in on how they handle the topic of obesity with their patients and the results were surprising.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?
- Olaratumab May Be Safe and Effective in Patients With Advanced Soft Tissue Sarcoma
- Next-Generation Sequencing May Benefit Some Patients With Sarcoma